Tasigna
Tasigna Uses, Dosage, Side Effects, Mechanism of Action, How Long Does it Take to Work? Tasigna is a brand name. Its generic name is Nilotinib.
Introduction
Tasigna is a prescription medication used to treat chronic myelogenous leukemia (CML). It belongs to a class of medications called tyrosine kinase inhibitors. Tasigna works by blocking signals inside the cancer cells that cause them to grow and spread.Uses for
Tasigna is used to treat adults with chronic phase, accelerated phase, or blast phase chronic myelogenous leukemia (CML) that no longer responds to other treatments. It is also used for adults who have not been treated with other medications for CML.Mechanism of Action
Tasigna works by blocking certain signals inside of the cells of the body. This includes signals within the cancer cells that cause them to grow and spread. By blocking these signals, nilotinib helps to slow down the growth and spread of the cancer cells.How Long Does it Take to Work?
Tasigna may take up to 8 weeks to work. People who take nilotinib may not see a decrease in their cancer until after 8 weeksAbsorption
Tasigna is absorbed rapidly after oral administration, with peak levels achieved within 2–4 hours.Route of Elimination
Tasigna is mainly eliminated in urine and feces. Less than 1% of nilotinib is eliminated unchanged in the urine.Dosage
Tasigna comes as a capsule that is taken by mouth twice daily, with or without food. The recommended dose for adults is 300mg twice daily.Administration
Tasigna should be taken by mouth twice a day with or without food. The tablets should be swallowed whole with plenty of water.Side Effect
The most common side effects of nilotinib include nausea, diarrhea, vomiting, joint or muscle pain, skin rash, fever, headache, fatigue, and edema.Toxicity
Tasigna can cause severe liver toxicity, which can be fatal. People taking nilotinib should be monitored for signs of liver toxicity including changes in blood tests.Precaution
People taking nilotinib should not take any other medications, including prescription and over-the-counter, without first talking to their healthcare provider.Interaction
Tasigna can interact with other medications, including certain antibiotics, antifungals, and certain antiseizure medications. It should not be taken with certain other medications, including some vitamins and herbal products.Disease Interaction
Tasigna can interact with certain diseases, including kidney or liver disease, or blood disorders. People with any of these conditions should talk to their healthcare provider before taking nilotinib.Drug Interaction
Tasigna can interact with certain drugs, including drugs used to treat HIV, certain anticonvulsants, and certain antibiotics. People taking any of these drugs should talk to their healthcare provider before taking nilotinib.Food Interactions
There are no known food interactions with nilotinib.Pregnancy Use
Tasigna should not be used during pregnancy unless the potential benefit outweighs the potential risks.Lactation Use
Tasigna should not be used while breastfeeding since it can be passed to the baby through breast milk.Acute Overdose
Symptoms of an acute nilotinib overdose can include seizures, loss of consciousness, vomiting, sweating, anxiety, and blurred vision.Contraindications
Tasigna should not be taken by people with an allergy to nilotinib or any of its ingredients. People with certain genetic disorders may also not be able to take nilotinib.Use Directions
Tasigna should be taken by mouth twice daily, with or without food, as directed by your healthcare provider. The tablets should be swallowed whole with plenty of water.Storage Condition
Tasigna capsules should be stored at room temperature away from moisture and heat.Volume of Distribution
The volume of distribution for nilotinib is approximately 17 liters.Half Life
The half-life of nilotinib is approximately 3.5 hours.Clearance
Tasigna has an average clearance of 19 liters/hour.Here you find in details version of Tasigna
Some Frequently Asked Questions About Tasigna
https://www.medicinesfaq.com/brand/tasigna,
,
,
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:52172,
http://www.hmdb.ca/metabolites/HMDB0015595,
http://www.genome.jp/dbget-bin/www_bget?drug:D08953,
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=644241,
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=99443226,
https://www.chemspider.com/Chemical-Structure.559260.html,
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50237710,
https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=662281,
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=52172,
https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL255863,
https://zinc.docking.org/substances/ZINC000006716957,
http://www.pharmgkb.org/drug/PA165958345,
https://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/NIL,
https://en.wikipedia.org/wiki/Nilotinib,